EIF2AK2 antibody (N-Term)

Catalog No. ABIN360663

This anti-EIF2AK2 antibody is a Rabbit Polyclonal antibody detecting EIF2AK2 in WB, IHC (p) and EIA. Suitable for Human and Mouse.

Quick Overview for EIF2AK2 antibody (N-Term) (ABIN360663)

Target: EIF2AK2 (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 (EIF2AK2))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EIF2AK2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Product Details anti-EIF2AK2 Antibody

Binding Specificity: N-Term

Specificity: This antibody reacts to PRKR.

Purification: Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

Immunogen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human PRKR.

Isotype: Ig Fraction

Application Details

Application Notes: ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100. Flow cytometry.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Target Details for EIF2AK2

Target: EIF2AK2 (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2 (EIF2AK2))

Alternative Name: EIF2AK2 / PKR

Background: Interferon-induced, double-stranded RNA-activated protein kinase (PRKR) is a serine-threonine kinase. Activation by dsRNAs leads to autophosphorylation of PRKR and allows the kinase to phosphorylate its natural substrate, the alpha subunit of eukaryotic protein synthesis initiation factor-2 (EIF2-alpha), leading to the inhibition of protein synthesis. Human gamma-interferon (IFNG) mRNA exploits localized activation of PRKR in the cell to regulate its own translation. IFNG mRNA activates PRKR through a pseudoknot in its 5-prime untranslated region. The HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PRKR and the translation initiation factor EIF2-alpha, a target of PRKR. E2 inhibits the kinase activity of PRKR and blocks its inhibitory effect on protein synthesis and cell growth, which provides one mechanism by which HCV may circumvent the antiviral effect of interferon. PRKR, which is involved in TLR signaling and mediates apoptosis in fibroblasts in response to viral infection and inflammatory cytokines, also activates IKK and NFKB, thereby suppressing apoptosis. Apoptosis induced by live pathogenic gram-positive and gram-negative bacteria requirs both TLR4 and PRKR, possibly representing a major mechanism for pathogenic bacteria that use specific virulence factors to avoid detection and destruction by the innate immune system. Roles for PRKR activation in Huntington disease and Fanconi anemia have also been suggested.Synonyms: Eukaryotic translation initiation factor 2-alpha kinase 2, Interferon-induced double-stranded RNA-activated protein kinase, PRKR, Protein kinase RNA-activated, eIF-2A protein kinase 2, p68 kinase

Gene ID: 5610

NCBI Accession: NP_001129123

UniProt: P19525

Pathways: DNA Damage Repair, ER-Nucleus Signaling, Hepatitis C